Johnson & Johnson $JNJ Shares Sold by TrueMark Investments LLC

TrueMark Investments LLC cut its stake in shares of Johnson & Johnson (NYSE:JNJ) by 18.9% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 31,242 shares of the company’s stock after selling 7,300 shares during the period. TrueMark Investments LLC’s holdings in Johnson & Johnson were worth $4,772,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. GFG Capital LLC purchased a new position in shares of Johnson & Johnson during the second quarter worth $35,000. Stone House Investment Management LLC purchased a new position in Johnson & Johnson during the 1st quarter valued at about $47,000. 1248 Management LLC acquired a new position in Johnson & Johnson in the 1st quarter valued at about $48,000. von Borstel & Associates Inc. purchased a new stake in Johnson & Johnson during the first quarter worth about $49,000. Finally, Harvest Fund Management Co. Ltd acquired a new stake in shares of Johnson & Johnson during the first quarter worth about $52,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Wells Fargo & Company set a $212.00 price objective on shares of Johnson & Johnson and gave the company an “overweight” rating in a report on Friday, October 3rd. The Goldman Sachs Group boosted their price target on shares of Johnson & Johnson from $186.00 to $212.00 and gave the stock a “buy” rating in a research note on Thursday, October 9th. HSBC upped their price objective on Johnson & Johnson from $210.00 to $215.00 and gave the stock a “buy” rating in a research report on Thursday. Morgan Stanley set a $190.00 target price on Johnson & Johnson in a report on Wednesday. Finally, Barclays upped their price target on Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a report on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $199.88.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $193.27 on Monday. The company has a market cap of $465.45 billion, a P/E ratio of 18.65, a PEG ratio of 2.27 and a beta of 0.40. The firm has a fifty day moving average price of $180.49 and a 200 day moving average price of $164.90. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $194.40.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The company had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 33.08% and a net margin of 27.26%. Sell-side analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.7%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is currently 50.19%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.